John Caminis

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

Dennis M. Black, Pierre D. Delmas, Richard Eastell et al. · New England Journal of Medicine · 2007 · 2.9K citations · Full text

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study

Michael R. McClung, Jacques P. Brown, Adolfo Díez‐Pérez et al. · Journal of Bone and Mineral Research · 2018 · 223 citations · Full text

Bone Disease, Bone Turnover Markers, Bone Health +14

First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q

Marcella Devoto, Koichiro Shimoya, John Caminis et al. · European Journal of Human Genetics · 1998 · 220 citations · Full text

Bone Disease, Chromosomes 1P, Developmental Biology +11

Treatment with Zoledronic Acid Ameliorates Negative Geometric Changes in the Proximal Femur following Acute Spinal Cord Injury

Jay R. Shapiro, Brian T. Smith, Thomas Beck et al. · Calcified Tissue International · 2007 · 88 citations

Spinal Cord Injury, Proximal Femur, Spinal Trauma +9

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures

Emil H. Schemitsch, Theodore Miclau, Theofilos Karachalios et al. · Journal of Bone and Joint Surgery · 2020 · 82 citations · Full text